GlassScriptPhysician profile
Adeel Afzal
NPI 1982866653
$3,796.16
in general payments reported to CMS, 2019-2025
28 companies · $14.26 in 2025
The $14.26 reported for 2025 was less than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $138 · 2020: $89.65 · 2021: $1,274 · 2022: $1,370 · 2023: $555 · 2024: $355 · 2025: $14.26.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $924.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $924.41 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $2,383.10 | 2021-2024 | Assurity, Gallant, Confirm Rx |
| Novartis Pharmaceuticals Corporation | $146.23 | 2021-2022 | |
| Paratek Pharmaceuticals, INC. | $139.15 | 2019-2022 | |
| Astellas Pharma US INC | $129.43 | 2021-2022 | |
| Shionogi INC | $122.61 | 2021-2023 | Fetroja |
| Lilly USA, LLC | $119.28 | 2021-2023 | Mounjaro |
| Dexcom, INC. | $111.46 | 2021-2023 | Dexcom G6 Transmitter |
| Astrazeneca Pharmaceuticals LP | $106.86 | 2021-2023 | Farxiga |
| Gilead Sciences, INC. | $58.29 | 2020-2023 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $58.26 | 2019-2021 | |
| Janssen Pharmaceuticals, INC | $52.60 | 2021 | |
| Janssen Biotech, INC. | $35.63 | 2019-2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $34.17 | 2021-2023 | Jardiance |
| Pfizer INC. | $30.01 | 2019-2025 | |
| Sunovion Pharmaceuticals INC. | $29.40 | 2022 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Viiv Healthcare Company | $25.97 | 2021 | |
| Novo Nordisk INC | $24.70 | 2020-2022 | |
| Melinta Therapeutics, LLC | $24.29 | 2019 | |
| Radius Health, INC. | $21.34 | 2020 | |
| Nabriva Therapeutics, Plc | $20.08 | 2021 | |
| Eisai INC. | $19.32 | 2021 | |
| Kowa Pharmaceuticals America, INC. | $16.97 | 2022 | |
| Tetraphase Pharmaceuticals, INC. | $16.93 | 2019 | |
| Esperion Therapeutics, INC. | $16.82 | 2020 | |
| Idorsia Pharmaceuticals US INC | $15.53 | 2023 | Quviviq |
| Smith+Nephew, INC. | $14.55 | 2019 | |
| Merck Sharp & Dohme LLC | $12.34 | 2019 | |
| Amarin Pharma, INC. | $10.84 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Adeel Afzal listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.